Zotepine: A clinical review

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 2, 2009, Pages 181-186

  Green, Ben ^a,b,c  

^a Cheadle Royal Hospital   (United Kingdom)

^b UNIVERSITY OF CHESTER   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Antipsychotic; Neuroleptic; Noradrenaline; Review; Schizophrenia; Zotepine

Indexed keywords

AMISULPRIDE; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CLOZAPINE; DIAZEPAM; FLUPENTIXOL; HALOPERIDOL; IMIPRAMINE; KETOCONAZOLE; NORFLUOXETINE; OLANZAPINE; PLACEBO; PROCYCLIDINE; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZOTEPINE;

AKATHISIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA AREATA; ANXIETY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BRONCHITIS; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; CONVULSION; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DRUG ACTIVITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH SERVICE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPOTHERMIA; HYPOURICEMIA; INSOMNIA; LABORATORY TEST; LOW DRUG DOSE; MANIA; MOTOR DYSFUNCTION; PROLACTIN BLOOD LEVEL; QT PROLONGATION; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; SUICIDE; TACHYCARDIA; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; UNITED KINGDOM; URIC ACID BLOOD LEVEL; WEIGHT GAIN; XEROSTOMIA;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIPSYCHOTIC AGENTS; DIBENZOTHIEPINS; GREAT BRITAIN; HUMANS; RECEPTORS, ADRENERGIC; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; SCHIZOPHRENIA;

EID: 67649122857     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250802670482     Document Type: Review

References (37)

1. Petit M, Raniwalla J, Tweed J, et al. A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double-blind trial. Psychopharmacol Bull 1996;32(1):81-87 (Pubitemid 26176206)
2. Yang SY, Kao Yang YH, Chong MY, et al. Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based study. Clin Pharmacol Ther 2007;81(4):586-594 (Pubitemid 46452302)
3. Palmgren K, Wighton A, Reynolds CW, et al. The safety and efficacy of zotepine in the treatment of schizophrenia: results of a one year naturalistic clinical trial. Int J Psychiatry Clin Practice 2000;4:299-306 (Pubitemid 32057653)
4. Amann B, Sterr A, Mergl R, et al. Zotepine loading in acute and severely manic patients: a pilot study. Bipolar Disorders 2005;7(5):471-476 (Pubitemid 41419415)
5. Young RC, Biggs JT, Ziegler VE, Meyer SA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133:429-435 (Pubitemid 9006756)
6. Cummings JL. The neuropsychiatric inventory: assessing psychopathology in patients with dementia. Neurology 1997;48:S10-6 (Pubitemid 27232698)
7. Koss E, Weiner M, Ernesto C, et al. Assessing patterns of agitation in Alzheimer's disease patients with the Cohen-Mansfield Agitation Inventory. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disorder 1997;11(Suppl 2):S45-50 (Pubitemid 127746696)
8. Rainer Michael KM, Mucke Hermann AM, Kruger-Rainer, et al. Zotepine for behavioural and psychological symptoms in dementia: an open-label study. CNS Drugs 2004;18(1):49-55 (Pubitemid 38197759)
9. Bonelli Raphael MN, Gerald L, et al. Zotepine in Huntington's disease. Hum Psychopharmacol 2003;18(3):227-229 (Pubitemid 36526949)
10. Tatsumi M, Jansen K, Blakely RD, Richelson E. Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol 1999;368(2-3):277-283 (Pubitemid 29117150)
11. Rowley H, Kilpatrick IC, Needham PL, Heal DJ. Elevation of extracellular cortical noradrenaline may contribute to the antidepressant activity of zotepine: an in vivo microdialysis study in freely moving rats. Neuropharmacology 1998;37(7):937-944 (Pubitemid 28375760)
12. Shiraga T, Kaneko H, Iwasaki K, et al. Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica 1999;29(3):217-229 (Pubitemid 29140092)
13. Tanaka O. Pharmacokinetics of zotepine and various factors affecting that of zotepine. Nihon Shinkei Seishin Yakurigaku Zasshi 1996;16(2):49-52 (Pubitemid 26198938)
14. Overall JE, Gorham DR. Introduction - The Brief Psychiatric Rating Scale (BPRS). Recent developments in ascertainment and scaling. Psychopharmacol Bull 1988;24:97-99
15. Andreasen NC. The Scale for the Assessment of Negative symptoms (SANS): Conceptual and theoretical foundation. Br J Psychiatry 1989;155(Suppl 7):49-58 (Pubitemid 19270849)
16. Simpson GM, Angus JSW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;45(Suppl):11-19
17. Guy W. ECDEU Assessment Manual for Psychopharmacology, revised ed. Washington, DC, US Department of Health, Education, and Welfare, 1976
18. Cooper SJ, Butler A, Tweed J, et al. Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia. Psychopharmacology 2000;150(3):237-243 (Pubitemid 30447842)
19. Hwang T, Lin SK, Lin HN. Efficacy and safety of zotepine for the treatment of Taiwanese schizophrenic patients: a double-blind comparison with haloperidol. J Formos Med Assoc 2001;100(12):811-816 (Pubitemid 34071802)
20. Cooper SJ, Tweed J, Raniwalla J, et al. placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. Acta Psychiatrica Scandinavica 2000;101(3):218-225 (Pubitemid 30108372)
21. Briken P, Nika E, Moritz S, et al. Effect of zotepine, olanzapine and risperidone on hostility in schizophrenic patients. Schizophrenia Research. 2002;57:311-313 (Pubitemid 35240035)
22. Harada T, Otsuki S, Sato M, et al. Effectivity of zotepine in refractory psychoses: possible relationships between zotepine and non-dopamine psychosis. Pharmacopsychiatry 1987;20:47-51 (Pubitemid 17042534)
23. Hashimoto K, Sudo T, Hirano M, et al. Efficacy and safety of zotepine for patients with treatment-resistant schizophrenia. Schizophr Res 2006;87(1-3):332-333 (Pubitemid 44428119)
24. Moller HJ, Riedel M, Muller N, et al. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial. Pharmacopsychiatry 2004;37(6):270-278 (Pubitemid 39587054)
25. Meyer-Lindenberg A, Gruppe H, Bauer U, et al. Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study. Pharmacopsychiatry 1997;30(2):35-42 (Pubitemid 27158038)
26. Barnas C, Stuppack CH, Miler C, et al. Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms. A double-blind trial vs. haloperidol. Int Clin Psychopharmacol 1992;7:23-27
27. Dieterle DM, Albus MI, Eben E, et al. Preliminary experiences and results with the Munich version of the Andreasen scale. Pharmacopsychiatry 1991;19:96-100
28. Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 2004;64(7):701-723 (Pubitemid 38471372)
29. Taylor DM, McAskill R. Atypical antipsychotics and weight gain - a systematic review. Acta Psychiatrica Scandinavica 2000;101(6):416-432 (Pubitemid 30365564)
30. Wetterling T. Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf 2001;24(1):59-73
31. Mackin Paul. Cardiac side effects of psychiatric drugs. Hum Psychopharmacol 2008;23(Suppl 1):3-14 (Pubitemid 351166608)
32. Svestka J, Synek O, Tomanova J, et al. Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-lab el trial in female in-patients. Neuroendocrinol Lett 2007;28(6):881-888
33. Kubota T, Ishikura T, Jibiki I. Three cases of alopecia areata induced by zotepine. Acta Neurologica 1993;15(3):200-203 (Pubitemid 23247937)
34. Chen KAO, Yang Yen Kuang, Chen Po See, et al. Two case studies of hypothermia induced by an increased dosage of zotepine in a combination therapy. Psychiatry Clin Neurosci 2003;57(4):369-371 (Pubitemid 36958807)
35. Medicines and Healthcare Products Regulatory Agency (UK) Drug Analysis Print- Zotepine. Accessed September 2008. Available from: http://www.mhra.gov. uk/Safetyinformation/Howwemonitorthesafetyofproducts/Medicines/ TheYellowCardScheme/YellowCarddata/Druganalysisprints/index. htm?indexChar=Z
36. Kondo T, Tanaka O, Otani K, et al. Possible inhibitory effect of diazepam on the metabolism of zotepine, an antipsychotic drug. Psychopharmacology 1996;1274:311-314 (Pubitemid 26356755)
37. DeSilva P, Fenton M, Rathbone J. Zotepine for schizophrenia. [update of Cochrane Database Syst Rev 2000;(2):CD001948; PMID: 10796671]. Cochrane Database Syst Rev 2006;4:CD001948